The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye

 

 Buy Article Permissions and Reprints

Abstract

The expression of several components of the plasminogen–plasmin (P–P) system in tumor tissues has been shown to have prognostic significance in many human cancers, including those of the breast, prostate, lung, brain, ovary, stomach, colon, rectum, oral cavity, kidney, and bone. Mechanisms of action of the individual components have been extensively studied in tumor cells in vitro and in animal models. By interrupting various putative pathways involved in tumor progression in several experimental tumor models in animals, varying degrees of tumor control have been achieved. However, these efforts have thus far not been able to exert any impact in oncologic clinical practice. A possible explanation is our incomplete understanding of the complex involvement of the P–P system and its interactions with other tumorigenic factors. In this article, the role of various members of the P–P system in cancer is reviewed. Proteolysis via the urokinase-type plasminogen activator–plasminogen activation pathway tends to enhance tumor growth and invasion, and its natural inhibitor plasminogen activator inhibitor type 1 may also enhance tumor growth through the inhibition of apoptosis, enhancing cell proliferation and the promotion of angiogenesis. Meaningful drug designs for therapeutic intervention require a thorough understanding of the role of all of the components involved in this complex mechanism of tumor progression.

• References

• 1 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7 (1) 4-13
  CrossrefPubMedGoogle Scholar
• 2 Danø K, Behrendt N, Høyer-Hansen G , et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93 (4) 676-681
  PubMedGoogle Scholar
• 3 Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66
  PubMedGoogle Scholar
• 4 Binder BR, Mihaly J. The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett 2008; 118 (2) 116-124
  CrossrefPubMedGoogle Scholar
• 5 Heinemann V, Ebert M, Pinter T, Mala C, Neville N, Bevan P. Randomised Phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced non-metastatic pancreatic cancer. European Society of Medical Oncology (ESMO). 2010; ; Abstract 712PD
  PubMedGoogle Scholar
• 6 Goldstein LJ, Oliveria CT, Heinrich B , et al. A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabinemonotherapy in first-line HER2- negative metastatic breast cancer (MBC). CTRC-AACR San Antonio Breast Cancer Symposium 2012; :5–20–01
  PubMedGoogle Scholar
• 7 Kwaan HC, Keer HN, Radosevich JA, Cajot JF, Ernst R. Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost 1991; 17 (3) 175-182
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Mondino A, Resnati M, Blasi F. Structure and function of the urokinase receptor. Thromb Haemost 1999; 82 (Suppl. 01) 19-22
  PubMedGoogle Scholar
• 9 Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001; 86 (1) 124-129
  PubMedGoogle Scholar
• 10 Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001; 12 (10) 2975-2986
  CrossrefPubMedGoogle Scholar
• 11 Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell 2001; 12 (5) 1467-1479
  CrossrefPubMedGoogle Scholar
• 12 Tarui T, Andronicos N, Czekay RP , et al. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem 2003; 278 (32) 29863-29872
  CrossrefPubMedGoogle Scholar
• 13 Cortese K, Sahores M, Madsen CD, Tacchetti C, Blasi F. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS ONE 2008; 3 (11) e3730
  CrossrefPubMedGoogle Scholar
• 14 Andreasen PA. PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets 2007; 8 (9) 1030-1041
  CrossrefPubMedGoogle Scholar
• 15 Bajou K, Masson V, Gerard RD , et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152 (4) 777-784
  CrossrefPubMedGoogle Scholar
• 16 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3 (12) 932-943
  CrossrefPubMedGoogle Scholar
• 17 Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 2008; 100 (6) 1029-1036
  PubMedGoogle Scholar
• 18 Bajou K, Peng H, Laug WE , et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14 (4) 324-334
  CrossrefPubMedGoogle Scholar
• 19 Soff GA, Sanderowitz J, Gately S , et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96 (6) 2593-2600
  CrossrefPubMedGoogle Scholar
• 20 Cajot JF, Bamat J, Bergonzelli GE , et al. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A 1990; 87 (18) 6939-6943
  CrossrefPubMedGoogle Scholar
• 21 Alizadeh H, Ma D, Berman M , et al. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 1995; 14 (6) 449-458
  CrossrefPubMedGoogle Scholar
• 22 Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103 (3) 955-962
  PubMedGoogle Scholar
• 23 Okumura Y, Kamikubo Y, Curriden SA , et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 2002; 277 (11) 9395-9404
  CrossrefPubMedGoogle Scholar
• 24 Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160 (5) 781-791
  CrossrefPubMedGoogle Scholar
• 25 Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N, Merchan JR. Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects. Mol Cancer Res 2012; 10 (10) 1271-1281
  CrossrefPubMedGoogle Scholar
• 26 Soeda S, Shinomiya K, Ochiai T , et al. Plasminogen activator inhibitor-1 aids nerve growth factor-induced differentiation and survival of pheochromocytoma cells by activating both the extracellular signal-regulated kinase and c-Jun pathways. Neuroscience 2006; 141 (1) 101-108
  CrossrefPubMedGoogle Scholar
• 27 Zhang YP, Wang WL, Liu J , et al. Plasminogen activator inhibitor-1 promotes the proliferation and inhibits the apoptosis of pulmonary fibroblasts by Ca(2+) signaling. Thromb Res 2013; 131 (1) 64-71
  CrossrefPubMedGoogle Scholar
• 28 Devy L, Blacher S, Grignet-Debrus C , et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16 (2) 147-154
  CrossrefPubMedGoogle Scholar
• 29 Lambert V, Munaut C, Carmeliet P , et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci 2003; 44 (6) 2791-2797
  CrossrefPubMedGoogle Scholar
• 30 Bajou K, Masson V, Gerard RD , et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152 (4) 777-784
  CrossrefPubMedGoogle Scholar
• 31 Eden G, Archinti M, Furlan F, Murphy R, Degryse B. The urokinase receptor interactome. Curr Pharm Des 2011; 17 (19) 1874-1889
  CrossrefPubMedGoogle Scholar
• 32 Gårdsvoll H, Gilquin B, Le Du MH, Ménèz A, Jørgensen TJ, Ploug M. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem 2006; 281 (28) 19260-19272
  CrossrefPubMedGoogle Scholar
• 33 Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16 (24) 7279-7286
  CrossrefPubMedGoogle Scholar
• 34 Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12 (5) 613-620
  CrossrefPubMedGoogle Scholar
• 35 Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137 (3) 767-777
  CrossrefPubMedGoogle Scholar
• 36 Nowicki TS, Zhao H, Darzynkiewicz Z , et al. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011; 10 (1) 100-107
  CrossrefPubMedGoogle Scholar
• 37 Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 2007; 31 (1) 19-27
  PubMedGoogle Scholar
• 38 Eastman BM, Jo M, Webb DL, Takimoto S, Gonias SL. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. Cell Signal 2012; 24 (9) 1847-1855
  CrossrefPubMedGoogle Scholar
• 39 Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets 2011; 12 (12) 1744-1760
  CrossrefPubMedGoogle Scholar
• 40 Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000; 19 (17) 4817-4826
  CrossrefPubMedGoogle Scholar
• 41 Høyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007; 44: 65-102
  PubMedGoogle Scholar
• 42 Sorio C, Mafficini A, Furlan F , et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011; 11: 448
  CrossrefPubMedGoogle Scholar
• 43 Lomholt AF, Høyer-Hansen G, Nielsen HJ, Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer 2009; 101 (6) 992-997
  CrossrefPubMedGoogle Scholar
• 44 Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008; 14 (18) 5785-5793
  CrossrefPubMedGoogle Scholar
• 45 Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277 (49) 46932-46939
  CrossrefPubMedGoogle Scholar
• 46 Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008; 14 (18) 5649-5655
  CrossrefPubMedGoogle Scholar
• 47 Rao JS, Gopinath S, Malla RR , et al. Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression. Carcinogenesis 2012;
  PubMedGoogle Scholar
• 48 Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, Gonias SL. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res 2010; 70 (21) 8948-8958
  CrossrefPubMedGoogle Scholar
• 49 Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int J Oncol 2010; 37 (2) 437-444
  PubMedGoogle Scholar
• 50 Alexander RA, Prager GW, Mihaly-Bison J , et al. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012; 94 (1) 125-135
  CrossrefPubMedGoogle Scholar
• 51 Breuss JM, Uhrin P. VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adhes Migr 2012; 6 (6) 535-615
  CrossrefPubMedGoogle Scholar
• 52 Harris L, Fritsche H, Mennel R , et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25 (33) 5287-5312
  CrossrefPubMedGoogle Scholar
• 53 Look MP, van Putten WL, Duffy MJ , et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94 (2) 116-128
  CrossrefPubMedGoogle Scholar
• 54 Jänicke F, Prechtl A, Thomssen C , et al; German N0 Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93 (12) 913-920
  CrossrefPubMedGoogle Scholar
• 55 Harbeck N, Kates RE, Look MP , et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002; 62 (16) 4617-4622
  PubMedGoogle Scholar
• 56 Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20 (4) 1000-1007
  CrossrefPubMedGoogle Scholar
• 57 Foekens JA, Buessecker F, Peters HA , et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55 (7) 1423-1427
  PubMedGoogle Scholar
• 58 Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O'Higgins NJ. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998; 44 (6 Pt 1) 1177-1183
  PubMedGoogle Scholar
• 59 Grøndahl-Hansen J, Peters HA, van Putten WL , et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1 (10) 1079-1087
  PubMedGoogle Scholar
• 60 Sternlicht MD, Dunning AM, Moore DH , et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006; 15 (11) 2107-2114
  CrossrefPubMedGoogle Scholar
• 61 Annecke K, Schmitt M, Euler U , et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008; 45: 31-45
  PubMedGoogle Scholar
• 62 Schmitt M, Harbeck N, Brünner N , et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011; 11 (6) 617-634
  CrossrefPubMedGoogle Scholar
• 63 Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87 (10) 751-756
  CrossrefPubMedGoogle Scholar
• 64 Gutova M, Najbauer J, Gevorgyan A , et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2007; 2 (2) e243
  CrossrefPubMedGoogle Scholar
• 65 Hataji O, Taguchi O, Gabazza EC , et al. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004; 76 (3) 214-219
  CrossrefPubMedGoogle Scholar
• 66 Bauer TW, Liu W, Fan F , et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65 (17) 7775-7781
  PubMedGoogle Scholar
• 67 Rabbani SA, Ateeq B, Arakelian A , et al. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 2010; 12 (10) 778-788
  CrossrefPubMedGoogle Scholar
• 68 Kenny HA, Leonhardt P, Ladanyi A , et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 2011; 17 (3) 459-471
  CrossrefPubMedGoogle Scholar
• 69 Van Buren II G, Gray MJ, Dallas NA , et al. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009; 115 (14) 3360-3368
  CrossrefPubMedGoogle Scholar
• 70 Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9 (1) 32-71
  CrossrefPubMedGoogle Scholar
• 71 Ngo JC, Jiang L, Lin Z , et al. Structural basis for therapeutic intervention of uPA/uPAR system. Curr Drug Targets 2011; 12 (12) 1729-1743
  CrossrefPubMedGoogle Scholar
• 72 Jensen JK, Thompson LC, Bucci JC , et al. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 2011; 286 (34) 29709-29717
  CrossrefPubMedGoogle Scholar
• 73 Nienaber V, Wang J, Davidson D, Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem 2000; 275 (10) 7239-7248
  CrossrefPubMedGoogle Scholar
• 74 Xu X, Gårdsvoll H, Yuan C, Lin L, Ploug M, Huang M. Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol 2012; 416 (5) 629-641
  CrossrefPubMedGoogle Scholar
• 75 Huai Q, Mazar AP, Kuo A , et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311 (5761) 656-659
  CrossrefPubMedGoogle Scholar
• 76 Law RH, Caradoc-Davies T, Cowieson N , et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012; 1 (3) 185-190
  CrossrefPubMedGoogle Scholar
• 77 Weisberg AD, Albornoz F, Griffin JP , et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005; 25 (2) 365-371
  PubMedGoogle Scholar
• 78 Hennan JK, Morgan GA, Swillo RE , et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008; 6 (9) 1558-1564
  PubMedGoogle Scholar
• 79 Hennan JK, Elokdah H, Leal M , et al. Evaluation of PAI-039 [1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 2005; 314 (2) 710-716
  CrossrefPubMedGoogle Scholar
• 80 Pandya V, Jain M, Chakrabarti G , et al. Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives. Bioorg Med Chem Lett 2011; 21 (19) 5701-5706
  CrossrefPubMedGoogle Scholar
• 81 Brown NJ. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010; 4 (5) 315-324
  CrossrefPubMedGoogle Scholar
• 82 Yamaoka N, Kawano Y, Izuhara Y, Miyata T, Meguro K. Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors. Chem Pharm Bull (Tokyo) 2010; 58 (5) 615-619
  CrossrefPubMedGoogle Scholar
• 83 Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets 2007; 8 (9) 962-970
  CrossrefPubMedGoogle Scholar
• 84 Cale JM, Li SH, Warnock M , et al. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 2010; 285 (11) 7892-7902
  CrossrefPubMedGoogle Scholar
• 85 Van De Craen B, Scroyen I, Vranckx C , et al. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb Res 2012; 129 (4) e126-e133
  CrossrefPubMedGoogle Scholar
• 86 Van De Craen B, Scroyen I, Abdelnabi R , et al. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. Thromb Res 2011; 128 (1) 68-76
  CrossrefPubMedGoogle Scholar
• 87 Katz BA, Mackman R, Luong C , et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol 2000; 7 (4) 299-312
  CrossrefPubMedGoogle Scholar
• 88 Subasinghe NL, Illig C, Hoffman J , et al. Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. Bioorg Med Chem Lett 2001; 11 (11) 1379-1382
  CrossrefPubMedGoogle Scholar
• 89 Sperl S, Jacob U, Arroyo de Prada N , et al. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc Natl Acad Sci U S A 2000; 97 (10) 5113-5118
  CrossrefPubMedGoogle Scholar
• 90 Meyer JE, Brocks C, Graefe H , et al. The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma. Breast Care (Basel) 2008; 3 (s2) 20-24
  PubMedGoogle Scholar
• 91 Danø K, Rømer J, Nielsen BS , et al. Cancer invasion and tissue remodeling—cooperation of protease systems and cell types. APMIS 1999; 107 (1) 120-127
  CrossrefPubMedGoogle Scholar
• 92 Wang F, Eric Knabe W, Li L , et al. Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem 2012; 20 (15) 4760-4773
  CrossrefPubMedGoogle Scholar
• 93 Kriegbaum MC, Persson M, Haldager L , et al. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets 2011; 12 (12) 1711-1728
  CrossrefPubMedGoogle Scholar
• 94 Ploug M, Østergaard S, Gårdsvoll H , et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40 (40) 12157-12168
  CrossrefPubMedGoogle Scholar
• 95 Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 2011; 9 (4) 377-389
  CrossrefPubMedGoogle Scholar
• 96 Gondi CS, Rao JS. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 2009; 487: 267-281
  PubMedGoogle Scholar
• 97 de Virgilio M, Silvestris F. Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapy. Curr Pharm Des 2011; 17 (19) 1979-1983
  CrossrefPubMedGoogle Scholar
• 98 Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem 2010; 285 (35) 26878-26888
  CrossrefPubMedGoogle Scholar
• 99 Harbeck N, Kates RE, Schmitt M , et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004; 5 (5) 348-352
  CrossrefPubMedGoogle Scholar
• 100 Ji F, Chen YL, Jin EY, Wang WL, Yang ZL, Li YM. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 2005; 11 (21) 3222-3226
  PubMedGoogle Scholar
• 101 Heiss MM, Babic R, Allgayer H , et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13 (8) 2084-2093
  PubMedGoogle Scholar
• 102 Nekarda H, Schmitt M, Ulm K , et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54 (11) 2900-2907
  PubMedGoogle Scholar
• 103 Zhang L, Zhao ZS, Ru GQ, Ma J. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 2006; 12 (25) 3970-3976
  PubMedGoogle Scholar
• 104 Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 1997; 79 (5) 878-883
  CrossrefPubMedGoogle Scholar
• 105 Stephens RW, Nielsen HJ, Christensen IJ , et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91 (10) 869-874
  CrossrefPubMedGoogle Scholar
• 106 Riisbro R, Christensen IJ, Nielsen HJ, Brünner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 2005; 20 (2) 93-102
  PubMedGoogle Scholar
• 107 Skelly MM, Troy A, Duffy MJ , et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997; 3 (10) 1837-1840
  PubMedGoogle Scholar
• 108 Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344 (8919) 401-402
  CrossrefPubMedGoogle Scholar
• 109 Torzewski M, Sarbia M, Verreet P , et al. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 1997; 3 (12 Pt 1) 2263-2268
  PubMedGoogle Scholar
• 110 Nekarda H, Schlegel P, Schmitt M , et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998; 4 (7) 1755-1763
  PubMedGoogle Scholar
• 111 Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000; 156 (2) 567-575
  CrossrefPubMedGoogle Scholar
• 112 Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995; 147 (1) 114-123
  PubMedGoogle Scholar
• 113 Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994; 54 (4) 1105-1108
  PubMedGoogle Scholar
• 114 Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 2001; 12 (1) 51-58
  CrossrefPubMedGoogle Scholar
• 115 Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996; 78 (3) 487-492
  CrossrefPubMedGoogle Scholar
• 116 Swiercz R, Wolfe JD, Zaher A, Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 1998; 4 (4) 869-877
  PubMedGoogle Scholar
• 117 Shariat SF, Roehrborn CG, McConnell JD , et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25 (4) 349-355
  CrossrefPubMedGoogle Scholar
• 118 Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39 (2) 123-129
  CrossrefPubMedGoogle Scholar
• 119 Hienert G, Kirchheimer JC, Pflüger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988; 140 (6) 1466-1469
  PubMedGoogle Scholar
• 120 Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994; 54 (24) 6539-6548
  PubMedGoogle Scholar
• 121 Kuhn W, Schmalfeldt B, Reuning U , et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79 (11-12) 1746-1751
  CrossrefPubMedGoogle Scholar
• 122 De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 1998; 58 (10) 2234-2239
  PubMedGoogle Scholar
• 123 Häckel CG, Krueger S, Grote HJ , et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 2000; 89 (5) 995-1003
  CrossrefPubMedGoogle Scholar